Search results
Results from the WOW.Com Content Network
Why Eli Lilly stock is under pressure. The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14 ...
On Wednesday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two ...
Eli Lilly just gave investors several reasons to cheer. ... This Is Huge News for Eli Lilly Investors. Adam Spatacco, The Motley Fool. December 19, 2024 at 1:44 AM.
Lilly's latest batch of positive news One of Lilly's biggest priorities right now is attaining FDA approval for donanemab. Donanemab is the company's candidate to treat Alzheimer's disease.
(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not ...
Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning ...
Eli Lilly stock is down after issuing Q4 2024 guidance ... In the latest weekly prescription tracking from JPMorgan, based on data from pharmaceutical data firm IQVIA, Zepbound's year-over-year ...
Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.